Rodman & Renshaw has recently initiated Sana Biotechnology Inc (SANA) stock to Buy rating, as announced on June 26, 2024, according to Finviz. Earlier, on January 16, 2024, H.C. Wainwright had raised the stock from a Neutral to Buy, setting a price target of $12. JMP Securities also initiated Mkt Outperform rating with a price target of $9. Additionally, Citigroup initiated Buy rating on September 5, 2023, with a target price of $8. TD Cowen analysts, in their report published on August 14, 2023, also initiated Market Perform rating for Sana Biotechnology Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Sana Biotechnology Inc (SANA) Stock Trading Recap
On Monday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $4.16 which represents a decrease of $-0.12 or -2.80% from the prior close of $4.28. The stock opened at $4.3 and touched a low of $4.08 during the day, reaching a high of $4.34. The volume of shares traded was 2.29 million exceeding the average volume of 1.68 million.
SANA Stock Performance and Moving Averages
In recent trading, Sana Biotechnology Inc (SANA) stock price has shown some volatility, fluctuating 1.71% over the last five trades and -31.91% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -58.89%, and it has plunged by -23.95% in the previous three months. Currently, SANA is trading at -11.42%, -19.47%, and -38.09% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, SANA, a Healthcare sector stock, is trading -65.33% below its 52-week high but remains 51.55% above its 52-week low. The Average True Range (ATR) (14 days) of 0.35 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Sana Biotechnology Inc’s Profitability and Valuation Ratios
Sana Biotechnology Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -58.89%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Sana Biotechnology Inc’s market capitalization stands at $925.48 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 2.72, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 45.26% of Sana Biotechnology Inc (SANA)’s shares, while financial institutions hold 51.05%.
Notable insider trades include Mulligan Richard, Director at Sana Biotechnology Inc (SANA), who sold 150000 shares on Sep 24 ’24, at $4.08 each, totaling $0.61 million. On Sep 25 ’24, Mulligan Richard, Director, sold 150000 shares for $3.89 each, amounting to $0.58 million. Additionally, on Mar 08 ’24, Yang Patrick Y sold 25000 shares at $9.45 each, generating $0.24 million.
